Back to Search Start Over

Overall mutational spectrum of SLC20A2, PDGFB and PDGFRB in idiopathic basal ganglia calcification

Authors :
Christine Tranchant
Dominique Campion
Cyril Pottier
Didier Hannequin
Emmanuel Roze
Christophe Verny
Franck Durif
Mathieu Anheim
Pascal Favrole
Gaël Nicolas
Anne-Claire Richard
Thierry Frebourg
Gabrielle Rudolf
Centre de recherche sur l'Inflammation (CRI (UMR_S_1149 / ERL_8252 / U1149))
Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Diderot - Paris 7 (UPD7)
Service de neurologie [Rouen]
CHU Rouen
Normandie Université (NU)-Normandie Université (NU)
Biologie Neurovasculaire Intégrée (BNVI)
Université d'Angers (UA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)
Neuro-Psycho Pharmacologie des Systèmes Dopimanégiques sous-corticaux - Clermont Auvergne (NPsy-Sydo)
CHU Clermont-Ferrand-Université Clermont Auvergne (UCA)
Institut du Cerveau et de la Moëlle Epinière = Brain and Spine Institute (ICM)
Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [APHP]-Centre National de la Recherche Scientifique (CNRS)
Fédération de Médecine Translationnelle de Strasbourg (FMTS)
Université de Strasbourg (UNISTRA)
Département de Neurologie
CHU Strasbourg-Hopital Civil
Génétique du cancer et des maladies neuropsychiatriques (GMFC)
Université de Rouen Normandie (UNIROUEN)
Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM)
Neuro-Psycho Pharmacologie des Systèmes Dopimanégiques sous-corticaux (NPsy-Sydo)
CHU Clermont-Ferrand-Université Clermont Auvergne [2017-2020] (UCA [2017-2020])
Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-CHU Pitié-Salpêtrière [AP-HP]
Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)
Université Paris Diderot - Paris 7 (UPD7)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)
Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [AP-HP]
Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS)
Source :
neurogenetics, neurogenetics, Springer Verlag, 2014, 15 (3), pp.215-216. ⟨10.1007/s10048-014-0404-2⟩, neurogenetics, 2014, 15 (3), pp.215-216. ⟨10.1007/s10048-014-0404-2⟩
Publication Year :
2014

Abstract

Familial idiopathic basal ganglia calcification (IBGC) or Fahr’s disease is a rare neurodegenerative disorder characterized by calcium deposits in the basal ganglia and other brain regions, which is associated with neuropsychiatric and motor symptoms. Familial IBGC is genetically heterogeneous and typically transmitted in an autosomal dominant fashion. We performed a mutational analysis of SLC20A2, the first gene found to cause IBGC, to assess its genetic contribution to familial IBGC. We recruited 218 subjects from 29 IBGC-affected families of varied ancestry and collected medical history, neurological exam, and head CT scans to characterize each patient’s disease status. We screened our patient cohort for mutations in SLC20A2. Twelve novel (nonsense, deletions, missense, and splice site) potentially pathogenic variants, one synonymous variant, and one previously reported mutation were identified in 13 families. Variants predicted to be deleterious cosegregated with disease in five families. Three families showed nonsegregation with clinical disease of such variants, but retrospective review of clinical and neuroimaging data strongly suggested previous misclassification. Overall, mutations in SLC20A2 account for as many as 41 % of our familial IBGC cases. Our screen in a large series expands the catalog of SLC20A2 mutations identified to date and demonstrates that mutations in SLC20A2 are a major cause of familial IBGC. Non-perfect segregation patterns of predicted deleterious variants highlight the challenges of phenotypic assessment in this condition with highly variable clinical presentation.

Details

ISSN :
13646753 and 13646745
Volume :
15
Issue :
3
Database :
OpenAIRE
Journal :
Neurogenetics
Accession number :
edsair.doi.dedup.....a260c3b0149c9f91516ba6e15f9b168c
Full Text :
https://doi.org/10.1007/s10048-014-0404-2⟩